| Megan Kathleen Hallock, PA-C | |
|
4330 Elmore Rd, Anchorage, AK 99508-5907 | |
| (907) 729-6690 | |
| Not Available |
| Full Name | Megan Kathleen Hallock |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 8 Years |
| Location | 4330 Elmore Rd, Anchorage, Alaska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346765708 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | 120168 (Alaska) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southcentral Foundation | 5496663627 | 112 |
News Archive
"All Americans should take pride in the fact that the world is on the verge of eradicating polio, and finishing the job for good has never been more achievable," Tufts Health Plan President and CEO James Roosevelt writes in The Hill's "Global Affairs" blog.
Veran Medical Technologies announced today that it has completed a round of financing worth more than $15M. Participants in the financing included existing investors and a new strategic partner.
During a Wednesday news conference, the Obama administration is expected to unveil regulations showing which preventive services insurers will be required to provide free-of-charge to consumers under the health overhaul law, The Wall Street Journal reports.
Codexis, Inc. announced today the pricing of its initial public offering of 6,000,000 shares of its common stock, at $13.00 per share. All shares are being sold by the company. Codexis has granted the underwriters an option to purchase up to an additional 900,000 shares at the initial public offering price to cover overallotments, if any. The common stock will trade on the NASDAQ Global Market under the symbol "CDXS."
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Megan Kathleen Hallock, PA-C 10271 Middlerock Rd, Anchorage, AK 99507-1229 Ph: (907) 378-6035 | Megan Kathleen Hallock, PA-C 4330 Elmore Rd, Anchorage, AK 99508-5907 Ph: (907) 729-6690 |
News Archive
"All Americans should take pride in the fact that the world is on the verge of eradicating polio, and finishing the job for good has never been more achievable," Tufts Health Plan President and CEO James Roosevelt writes in The Hill's "Global Affairs" blog.
Veran Medical Technologies announced today that it has completed a round of financing worth more than $15M. Participants in the financing included existing investors and a new strategic partner.
During a Wednesday news conference, the Obama administration is expected to unveil regulations showing which preventive services insurers will be required to provide free-of-charge to consumers under the health overhaul law, The Wall Street Journal reports.
Codexis, Inc. announced today the pricing of its initial public offering of 6,000,000 shares of its common stock, at $13.00 per share. All shares are being sold by the company. Codexis has granted the underwriters an option to purchase up to an additional 900,000 shares at the initial public offering price to cover overallotments, if any. The common stock will trade on the NASDAQ Global Market under the symbol "CDXS."
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
› Verified 5 days ago
Amanda Loomis, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 550 W 7th Ave Ste 1800, Anchorage, AK 99501 Phone: 907-269-7300 | |
Bryan Farthing, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 3841 Piper St, Suite T4-054, Anchorage, AK 99508 Phone: 907-562-6228 | |
Kimberley Turner, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 1400 E 4th Ave, Anchorage, AK 99501 Phone: 907-269-4234 Fax: 907-269-4235 | |
Corinne Faye Olivera, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 5005 Raspberry Rd, Building 9, Anchorage, AK 99502 Phone: 907-249-1276 Fax: 907-249-1145 | |
Mark Andrew Malzahn, P.A.-C. Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 4100 Lake Otis Pkwy, #302, Anchorage, AK 99508 Phone: 907-563-7072 Fax: 907-562-5742 | |
Mrs. Cynthia Jean Smith, PC-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 2550 Denali St, Anchorage, AK 99503 Phone: 907-375-8787 | |
Even R Evanson, PA-C Physician Assistant Medicare: May Accept Medicare Assignments Practice Location: 3841 Piper St, Suite T-100, Anchorage, AK 99508 Phone: 907-561-3211 Fax: 907-562-7547 |